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Dr Chuong D. Hoang (Stanford, Calif). I have nothing to
disclose.
Dr Pennathur and his group present a timely study showing that
traditional diagnostic and prognostic factors erroneously stratify
some patients some of the time, and I think his group has taken
a step forward into the future direction of personalized cancer
care. To be relevant, however, molecular prediction has to provide
additional information, independent of traditional criteria or pro-
vide prognostic information within the subgroups defined by those
traditional criteria. In this context, I have the following 3 questions.
First, could you please clarify whether any patients in your
study received neoadjuvant chemoradiotherapy, and, if so, howery c February 2013
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G
T
Swere you able to retrieve in all 69 resection specimens more than
70% tumor representation for subsequent array profiling? Is it not
surprising, here, that there were no pathologic complete re-
sponders in your prospective study?
Dr Pennathur. Thank you, Dr Hoang, for your kind comments.
The first question, patients who had neoadjuvant chemotherapy
or radiotherapy were excluded from the study because those have
an effect on gene expression. These patients are patients who were
not treated with neoadjuvant therapy.
Dr Hoang. Including the T3, T4 that you mentioned?
Dr Pennathur. Yes, including the patients who had T3 in the
final pathology analysis.
Dr Hoang. Question 2, the 2-dimensional heat map of your
gene classifier showed that there was imperfect representation of
some of the high-risk patients who were grouped into the low-
risk gene signature and vice versa. What was the specific error
rate in your prognostication? How did your gene classifier com-
parewith the old and now the newTNM staging systems for esoph-
ageal cancer? Furthermore, were you able to segregate by stage
how your classifier performed?
Dr Pennathur. Again, thank you for those questions.
The purpose of the heatmap classifier was to investigatewhether
any gene pattern existswith the potential to classify patient risk, and
the division into 2 groups (A and B) was based purely on the empir-
ical clustering of the patients. The specific error rate of classification
cannot be found in this context becausewe used survival as the end-
point—not class—and illustrated the classification accuracy, not
with an error rate but with survival differences between groups.
The gene risk signature was independent of the pathologic stage
of the prior system. Regarding the questions about the new staging
system, we have not yet actually compared this gene signaturewith
the new staging system.We do plan on performing an analysis with
the new staging system and will include this in the manuscript.
Dr Hoang.My final and third question is, by choosing a micro-
array-based prediction method, how do you plan to overcome
some of the inherent weaknesses in this technology that have lim-
ited its widespread application in daily clinical tests? This includes
that microarray tests are labor-intensive, time-consuming, and ex-
pensive, there are issues with reproducibility, and, usually, these
tests include many numbers of genes, making data handling im-
practical and cumbersome most of the time.
Dr Pennathur. I think that is a very relevant question. I think
these technologies are constantly evolving. As it stands, it is labor
intensive, and of course, the cost is a factor. We believe that over
time, as this technology evolves, the cost factor could be ad-
dressed, and anticipate that it will decrease. Also, ultimately I
think it is going to be a combination of molecular staging, clinical
staging, and known prognostic factors, which is going to help de-
termine the prognosis of the patient. I think if it really allows us to
choose a personalized treatment for a particular patient in terms of
the resection we are doing, in terms of the selection for multimo-
dality treatment for the individual patient that translates to im-
proved outcomes, then I think the efforts and costs are worth it,
but I agree that currently the costs are quite high, and as the tech-
nology improves, we think the cost will come down.
Dr Hoang. Thank you.
Dr Sandro Mattioli (Bologna, Italy). If I understood you, you
have demonstrated that your gene patterns do correspond to higherThe Journal of Thoracic and Castage tumors, which is good, but you are surely aware that some
tumors grow slowly and this would not help your aims. But the ma-
jor criticism is that you have put together apples and oranges, be-
cause you did not define the esophageal adenocarcinoma. Not all
esophageal adenocarcinomas are the same. Some stem from one
origin; some others stem from another origin. You did not show
how many of those cancers were associated with BE or not.
Thus, I think you are very far from your aiming point.
DrPennathur.Thankyou for your comments.With regard to your
second question, we presume that most of these cancers came from
BE; however, this was not done as a separate analysis. Our aim in
the current study was to investigate the gene expression profiles in
all patients with esophageal adenocarcinoma who underwent esoph-
agectomy with criteria as detailed in our inclusion/exclusion criteria,
andnot restrict this to specific stages or its specificorigin; sowe are on
target with the aims of the current study. We appreciate your com-
ments and will consider your suggestions for a future study. With re-
gard to your initial question and statement—regarding the pathologic
stage and gene expression—the gene classifier predicts risk in all
stages, for example, predicts high-risk T1 patients as well as low-
risk T3 patients. For example, even in the high-risk group, there
were a lot of superficial tumors—T1patients andT2patients, approx-
imately 50% of them in the high-risk group were T1 and T2 patients,
and roughly one third of T1 patients were in the high-risk group. So,
the high-risk gene signature was not exclusively seen in the higher
stage tumors. In fact, the gene risk signature was independent of the
pathologic stage in these patients. So, I think there is a gene signature
encoded early on that determines the survival in these patients.
Dr Keshavjee. I think that was the most important part of your
presentation, that high-risk group did represent some T1 and T2
and N0 patients, and that is unique.
Dr Thomas M. Egan (Chapel Hill, NC). You showed elevated
expression and reduced expression, but compared to what? Did
you have a control?
Dr Pennathur. That is a great question. We reviewed some of
the DNA microarray literature; our gene arrays had an implicit
control in the sense that arrays are normalized to the average array.
Differential expressions between groups are then relative but
because all arrays are normalized, comparisons are meaningful.
Recognizable gene differences are predicated on both fold changes
(ratios of differences) and low P values.
Dr Egan. But how can you identify those a priori? Was it based
on their survival?
Dr Pennathur.We use our model to predict each patient’s risk
of death and then use the median of estimated risk to divide them
into high-risk and low-risk groups.
Dr Egan. The other question is related to the potential for sam-
pling error. How did you know you were just getting tumor versus
tumor and underlying tissue?
Dr Pennathur. I think that is a great question. We made sure
that the pathologists, who were co-investigators, examined the tu-
mor to ensure there was more than 70% tumor representation, and
we believe the tumor tissue, along with the stromal tissue, has an
important bearing on how the tumor behaves. That is why we did
not use, for example, laser capture microscopy and we took the
gross tumor, which we believe is more representative.
Thank you for your comments. We thank the Association for the
opportunity to present this paper.rdiovascular Surgery c Volume 145, Number 2 513
